The good news is that CEO Mike Mahoney has helped Wall Street forget the lingering problems that once kept investors at bay, including billions of wasted capital on acquisitions that never panned out. But I'm not ready to bet that this company can be an outperformed. That's exactly what is presumed by the stock price.
Investors are hoping for positive results from the company's Watchman Left Atrial Appendage (LAA) device. Designed to be permanently implanted in patients to treat blood clots, the Watchman LAA device has significant potential.
Still, the company's attempt to get it to market keeps running into one snag after another. The U.S. Food and Drug Administration, which recently called for a third panel meeting to review the device, isn't making it easy. With no guarantees that the device will ever get to market, investors are letting better opportunities pass them buy.At the time of publication, the author held no positions in any of the stocks mentioned, although positions may change at any time. Follow @Richard_WSPB This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.
TheStreet Ratings team rates BOSTON SCIENTIFIC CORP as a Hold with a ratings score of C+. TheStreet Ratings Team has this to say about their recommendation:
"We rate BOSTON SCIENTIFIC CORP (BSX) a HOLD. The primary factors that have impacted our rating are mixed ? some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and weak operating cash flow." You can view the full analysis from the report here: BSX Ratings Report